<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03437564</url>
  </required_header>
  <id_info>
    <org_study_id>Vortioxetine-1001</org_study_id>
    <secondary_id>U1111-1208-2715</secondary_id>
    <secondary_id>JapicCTI-183863</secondary_id>
    <nct_id>NCT03437564</nct_id>
  </id_info>
  <brief_title>A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg Tablets</brief_title>
  <official_title>A Randomized, Open-Label, 2×2 Crossover Phase 1 Study to Evaluate the Bioequivalence of Single Oral Dose of Lu AA21004 20 mg Tablet and 2× Lu AA21004 10 mg Tablets in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the bioequivalence of a single oral administration
      of a vortioxetine (Lu AA21004) 20 mg tablet in comparison with two of vortioxetine 10 mg
      tablets in Japanese healthy adult participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called vortioxetine (Lu AA21004). Vortioxetine is
      being tested in Japanese healthy adult participants. This study will look at the
      bioequivalence of a single oral administration of a vortioxetine 20 mg tablet in comparison
      with two of vortioxetine 10 mg tablets, and also look at the safety of a single oral dose of
      vortioxetine 20 mg in Japanese healthy adult participants.

      The study will enroll 28 (14 for each sequence) healthy participants. In case bioequivalence
      cannot be demonstrated with the number of participants initially planned, an add-on
      participant study may be conducted (as a maximum 28 participants additionally). Participants
      will be randomly assigned (by chance, like flipping a coin) to one of the two treatment
      groups.

        -  Treatment Group A: Vortioxetine 20 mg (one 20 mg tablet) in Period 1 + Vortioxetine 20
           mg (two 10 mg tablets) in Period 2

        -  Treatment Group B: Vortioxetine 20 mg (two 10 mg tablets) in Period 1 + Vortioxetine 20
           mg (one 20 mg tablet) in Period 2

      This single-center trial will be conducted in Japan. The overall time to participate in this
      study is approximately 25 days. Participants will make two visits to the clinic and be
      hospitalized for ten days in total.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 16, 2018</start_date>
  <completion_date type="Actual">April 13, 2018</completion_date>
  <primary_completion_date type="Actual">April 13, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Quantifiable Time Point of Unchanged Lu AA21004</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax: Maximum Plasma Concentration (Observed Value) of Unchanged Lu AA21004</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC∞: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity of Unchanged Lu AA21004</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time to Reach Cmax (Observed Value) of Unchanged Lu AA21004</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRT∞, ev: Mean Residence Time 0 to Infinity of Unchanged Lu AA21004</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTlast, ev: Mean Residence Time From Time 0 to the Time of the Last Quantifiable Concentration of Unchanged Lu AA21004</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz: Apparent Elimination Rate Constant of Unchanged Lu AA21004</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2z: Apparent Elimination Half-Life of Unchanged Lu AA21004</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE)</measure>
    <time_frame>Up to Day 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With TEAE Related to Vital Sign</measure>
    <time_frame>Up to Day 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With TEAE Related to Clinical Laboratory Tests (Alanine Aminotransferase Increased)</measure>
    <time_frame>Up to Day 25</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With TEAE Related to 12-lead Electrocardiograms</measure>
    <time_frame>Up to Day 25</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Healthy Adult Participants</condition>
  <arm_group>
    <arm_group_label>Vortioxetine one 20 mg tablet + two 10 mg tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vortioxetine 20 mg (one 20 mg tablet) on Day 1 in Period 1 in a fasted state + vortioxetine 20 mg (two 10 mg tablets) on Day 1 in Period 2 in a fasted state.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vortioxetine two 10 mg tablets + one 20 mg tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vortioxetine 20 mg (two 10 mg tablets) on Day 1 in Period 1 in a fasted state + vortioxetine 20 mg (one 20 mg tablet) on Day 1 in Period 2 in a fasted state.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vortioxetine</intervention_name>
    <description>Vortioxetine tablet</description>
    <arm_group_label>Vortioxetine one 20 mg tablet + two 10 mg tablets</arm_group_label>
    <arm_group_label>Vortioxetine two 10 mg tablets + one 20 mg tablet</arm_group_label>
    <other_name>Lu AA21004</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be a healthy Japanese adult volunteer.

          2. Understand the contents of the study and is capable of providing written consent to
             participate in the study.

          3. Be willing to comply with all study procedures and restrictions.

          4. Aged between ≥20 and ≤45 years at the time of screening.

          5. Have a BMI of ≥18.5 and ≤24.9 (kg/m^2) and a body weight of ≥50 kg at the time of
             screening.

          6. Be a extensive metabolizer (EM) based on CYP2D6 genotyping at the time of screening.

          7. A female participant of childbearing potential with a non-sterilized male partner must
             agree to routinely use appropriate contraception during the study from the time of
             signing informed consent until 4 weeks after last dosing of the study drug.

        Exclusion Criteria:

          1. Has received any investigational drug within 90 days before screening for this study.

          2. Previously received Lu AA21004 before participation in this study.

          3. Is an employee of the sponsor or the study site, or immediate family member, or is in
             a dependent relationship with a study site employee who is involved in the conduct of
             this study (eg, spouse, parent, child, sibling) or who may be coerced to provide
             consent.

          4. Has uncontrolled, clinically relevant neurologic, cardiovascular, pulmonary, hepatic,
             renal, metabolic, gastrointestinal, or endocrine disease or other abnormality which
             may affect study participation or study results.

          5. Has a history of multiple episodes or severe allergies (eg, food, drug, latex allergy)
             or has had an anaphylactic reaction or significant intolerance to prescription drugs,
             over the counter (OTC) drugs, or foods.

          6. Has a positive pregnancy test at the time of screening or Day −1.

          7. Is a pregnant or lactating female.

          8. Has a positive urine drug screen test at the time of screening or Day −1.

          9. Has a history of drug abuse (defined as any illicit drug use) or has a history of
             alcohol dependence within 2 years before the start of screening or is unwilling to
             agree to abstain from alcohol and drugs throughout the study.

         10. Consumes 6 or more servings of caffeinated beverages (containing about 120 mg of
             caffeine per serving) such as of coffee, tea, cola, or energy drinks.

         11. Is a smoker who smoked cigarettes or used nicotine-containing products (such as
             nicotine patch) within 6 months before the Period 1 study drug administration.

         12. Used any of the excluded drugs, dietary products or foods during the specified time
             periods, or will need any of them during the study period.

         13. Has any current or recent gastrointestinal diseases that would be expected to
             influence the absorption of drugs (ie, a history of malabsorption, esophageal reflux,
             peptic ulcer disease, erosive esophagitis, frequent [more than once per week]
             occurrence of heartburn), or any surgical intervention (Stomach, cholecystectomy
             etc.).

         14. Has a history of cancer.

         15. Has a positive test result for any of the following at the time of screening:
             hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human
             immunodeficiency virus (HIV) antibody/antigen, serological test for syphilis.

         16. Has poor peripheral venous access.

         17. Has undergone whole blood collection of at least 200 mL within 4 weeks (28 days) or at
             least 400 mL within 12 weeks (84 days) prior to the start of Period 1 study drug
             administration.

         18. Has undergone whole blood collection of at least 800 mL in total within 52 weeks (364
             days) prior to the start of Period 1 study drug administration.

         19. Has undergone blood component collection within 2 weeks (14 days) prior to the start
             of Period 1 study drug administration.

         20. Has any clinically relevant abnormality in vital signs or 12-lead electrocardiograms
             (ECG) at screening or on Day −1 of Period 1.

         21. Has abnormal laboratory test values at screening or on Day −1 of Period 1 indicating
             clinically relevant underlying disease, or showing alanine aminotransferase (ALT)
             and/or aspartate aminotransferase (AST) &gt;1.5×upper limit of normal (ULN).

         22. Is unlikely to comply with the protocol requirements or is unsuitable as a participant
             of this study for any other reason in the opinion of the investigator or
             sub-investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nishi Kumamoto Hospital</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>February 13, 2018</study_first_submitted>
  <study_first_submitted_qc>February 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2018</study_first_posted>
  <results_first_submitted>April 2, 2019</results_first_submitted>
  <results_first_submitted_qc>April 2, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 26, 2019</results_first_posted>
  <last_update_submitted>June 26, 2019</last_update_submitted>
  <last_update_submitted_qc>June 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vortioxetine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 15, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT03437564/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT03437564/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 1 investigative site in Japan, from 16 February 2018 to 13 April 2018.</recruitment_details>
      <pre_assignment_details>Healthy participants were enrolled in one of two treatment group (vortioxetine 20 mg (1×20 mg tablet) on Day 1 in Period 1, followed by vortioxetine 20 mg (2×10 mg tablets) on Day 1 in Period 2; vortioxetine 20 mg (2×10 mg tablets) on Day 1 in Period 1, followed by vortioxetine 20 mg (1×20 mg tablet) on Day 1 in Period 2) with cross over design.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vortioxetine One 20 mg Tablet + Two 10 mg Tablets</title>
          <description>Vortioxetine 20 mg (one 20 mg tablet) orally, once on Day 1 in Period 1 in a fasted state + vortioxetine 20 mg (two 10 mg tablets) orally, once on Day 1 in Period 2 in a fasted state.</description>
        </group>
        <group group_id="P2">
          <title>Vortioxetine Two 10 mg Tablets + One 20 mg Tablet</title>
          <description>Vortioxetine 20 mg (two 10 mg tablets) orally, once on Day 1 in Period 1 in a fasted state + vortioxetine 20 mg (one 20 mg tablet) orally, once on Day 1 in Period 2 in a fasted state.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Pharmacokinetic (PK) Analysis Set; PK analysis set included all treated participants who had no major protocol violations, completed the minimum element of the protocol, and had evaluable pharmacokinetic data.</population>
      <group_list>
        <group group_id="B1">
          <title>Vortioxetine One 20 mg Tablet + Two 10 mg Tablets</title>
          <description>Vortioxetine 20 mg (one 20 mg tablet) orally, once on Day 1 in Period 1 in a fasted state + vortioxetine 20 mg (two 10 mg tablets) orally, once on Day 1 in Period 2 in a fasted state.</description>
        </group>
        <group group_id="B2">
          <title>Vortioxetine Two 10 mg Tablets + One 20 mg Table</title>
          <description>Vortioxetine 20 mg (two 10 mg tablets) orally, once on Day 1 in Period 1 in a fasted state + vortioxetine 20 mg (one 20 mg tablet) orally, once on Day 1 in Period 2 in a fasted state.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.0" spread="6.52"/>
                    <measurement group_id="B2" value="24.0" spread="4.96"/>
                    <measurement group_id="B3" value="24.0" spread="5.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>Centimeters (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172.4" spread="3.94"/>
                    <measurement group_id="B2" value="170.2" spread="6.48"/>
                    <measurement group_id="B3" value="171.3" spread="5.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kilograms (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.86" spread="6.694"/>
                    <measurement group_id="B2" value="61.91" spread="6.254"/>
                    <measurement group_id="B3" value="62.89" spread="6.434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <description>Body Mass Index = weight (kg)/[height (m)^2]</description>
          <units>kg/meter (m)^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.46" spread="1.812"/>
                    <measurement group_id="B2" value="21.33" spread="1.175"/>
                    <measurement group_id="B3" value="21.39" spread="1.500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Classification</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Never Smoked</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Ex-Smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol Classification</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Drank 2 to 3 Days a Week</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Drank 2 to 3 Days a Month</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Never Drank</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Caffeine Classification</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                    <count group_id="B2" value="14"/>
                    <count group_id="B3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Had Caffeine Consumption</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Had no Caffeine Consumption</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Quantifiable Time Point of Unchanged Lu AA21004</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose</time_frame>
        <population>Pharmacokinetic (PK) Analysis Set; PK analysis set included all treated participants who had no major protocol violations, completed the minimum element of the protocol, and had evaluable pharmacokinetic data.</population>
        <group_list>
          <group group_id="O1">
            <title>Vortioxetine One 20 mg Tablet</title>
            <description>Vortioxetine 20 mg (one 20 mg tablet) orally, once on Day 1 in Period 1 in a fasted state plus Day 1 in Period 2 in a fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine Two 10 mg Tablets</title>
            <description>Vortioxetine 20 mg (two 10 mg tablets) orally, once on Day 1 in Period 1 in a fasted state plus Day 1 in Period 2 in a fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Quantifiable Time Point of Unchanged Lu AA21004</title>
          <population>Pharmacokinetic (PK) Analysis Set; PK analysis set included all treated participants who had no major protocol violations, completed the minimum element of the protocol, and had evaluable pharmacokinetic data.</population>
          <units>hour*nanogram per milliliter (h*ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="299.3" spread="59.820"/>
                    <measurement group_id="O2" value="301.1" spread="62.070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in the least square (LS) means between the formulations (dosing of one Vortioxetine 20 mg tablet - dosing of two Vortioxetine 10 mg tablets) and the two-sided 90% confidence interval (CI) were provided using a crossover analysis of variance (ANOVA) model. The shown data were anti-logs of LS means difference and CI. The ANOVA model included log-transformed (natural log) PK parameters AUClast as dependent variable, and treatment condition, group, and period as independent variables.</non_inferiority_desc>
            <param_type>Point Estimate</param_type>
            <param_value>0.996</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.967</ci_lower_limit>
            <ci_upper_limit>1.026</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax: Maximum Plasma Concentration (Observed Value) of Unchanged Lu AA21004</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose</time_frame>
        <population>Pharmacokinetic (PK) Analysis Set; PK analysis set included all treated participants who had no major protocol violations, completed the minimum element of the protocol, and had evaluable pharmacokinetic data.</population>
        <group_list>
          <group group_id="O1">
            <title>Vortioxetine One 20 mg Tablet</title>
            <description>Vortioxetine 20 mg (one 20 mg tablet) orally, once on Day 1 in Period 1 in a fasted state plus Day 1 in Period 2 in a fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine Two 10 mg Tablets</title>
            <description>Vortioxetine 20 mg (two 10 mg tablets) orally, once on Day 1 in Period 1 in a fasted state plus Day 1 in Period 2 in a fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Plasma Concentration (Observed Value) of Unchanged Lu AA21004</title>
          <population>Pharmacokinetic (PK) Analysis Set; PK analysis set included all treated participants who had no major protocol violations, completed the minimum element of the protocol, and had evaluable pharmacokinetic data.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.744" spread="1.7838"/>
                    <measurement group_id="O2" value="8.976" spread="1.6936"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The difference in the LS means between the formulations (dosing of one vortioxetine 20 mg tablet - dosing of two vortioxetine 10 mg tablets) and the two-sided 90% CI were provided using a crossover ANOVA model. The shown data were anti-logs of LS means difference and CI. The ANOVA model included log-transformed (natural log) PK parameters Cmax as dependent variable, and treatment condition, group, and period as independent variables.</non_inferiority_desc>
            <param_type>Point Estimate</param_type>
            <param_value>0.972</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.937</ci_lower_limit>
            <ci_upper_limit>1.008</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC∞: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity of Unchanged Lu AA21004</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose</time_frame>
        <population>Pharmacokinetic (PK) Analysis Set; PK analysis set included all treated participants who had no major protocol violations, completed the minimum element of the protocol, and had evaluable pharmacokinetic data.</population>
        <group_list>
          <group group_id="O1">
            <title>Vortioxetine One 20 mg Tablet</title>
            <description>Vortioxetine 20 mg (one 20 mg tablet) orally, once on Day 1 in Period 1 in a fasted state plus Day 1 in Period 2 in a fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine Two 10 mg Tablets</title>
            <description>Vortioxetine 20 mg (two 10 mg tablets) orally, once on Day 1 in Period 1 in a fasted state plus Day 1 in Period 2 in a fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC∞: Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity of Unchanged Lu AA21004</title>
          <population>Pharmacokinetic (PK) Analysis Set; PK analysis set included all treated participants who had no major protocol violations, completed the minimum element of the protocol, and had evaluable pharmacokinetic data.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="463.9" spread="135.58"/>
                    <measurement group_id="O2" value="477.6" spread="164.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax: Time to Reach Cmax (Observed Value) of Unchanged Lu AA21004</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose</time_frame>
        <population>Pharmacokinetic (PK) Analysis Set; PK analysis set included all treated participants who had no major protocol violations, completed the minimum element of the protocol, and had evaluable pharmacokinetic data.</population>
        <group_list>
          <group group_id="O1">
            <title>Vortioxetine One 20 mg Tablet</title>
            <description>Vortioxetine 20 mg (one 20 mg tablet) orally, once on Day 1 in Period 1 in a fasted state plus Day 1 in Period 2 in a fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine Two 10 mg Tablets</title>
            <description>Vortioxetine 20 mg (two 10 mg tablets) orally, once on Day 1 in Period 1 in a fasted state plus Day 1 in Period 2 in a fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time to Reach Cmax (Observed Value) of Unchanged Lu AA21004</title>
          <population>Pharmacokinetic (PK) Analysis Set; PK analysis set included all treated participants who had no major protocol violations, completed the minimum element of the protocol, and had evaluable pharmacokinetic data.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.000" lower_limit="6.00" upper_limit="8.00"/>
                    <measurement group_id="O2" value="6.000" lower_limit="6.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MRT∞, ev: Mean Residence Time 0 to Infinity of Unchanged Lu AA21004</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose</time_frame>
        <population>Pharmacokinetic (PK) Analysis Set; PK analysis set included all treated participants who had no major protocol violations, completed the minimum element of the protocol, and had evaluable pharmacokinetic data.</population>
        <group_list>
          <group group_id="O1">
            <title>Vortioxetine One 20 mg Tablet</title>
            <description>Vortioxetine 20 mg (one 20 mg tablet) orally, once on Day 1 in Period 1 in a fasted state plus Day 1 in Period 2 in a fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine Two 10 mg Tablets</title>
            <description>Vortioxetine 20 mg (two 10 mg tablets) orally, once on Day 1 in Period 1 in a fasted state plus Day 1 in Period 2 in a fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>MRT∞, ev: Mean Residence Time 0 to Infinity of Unchanged Lu AA21004</title>
          <population>Pharmacokinetic (PK) Analysis Set; PK analysis set included all treated participants who had no major protocol violations, completed the minimum element of the protocol, and had evaluable pharmacokinetic data.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.27" spread="14.145"/>
                    <measurement group_id="O2" value="68.84" spread="18.646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>MRTlast, ev: Mean Residence Time From Time 0 to the Time of the Last Quantifiable Concentration of Unchanged Lu AA21004</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose</time_frame>
        <population>Pharmacokinetic (PK) Analysis Set; PK analysis set included all treated participants who had no major protocol violations, completed the minimum element of the protocol, and had evaluable pharmacokinetic data.</population>
        <group_list>
          <group group_id="O1">
            <title>Vortioxetine One 20 mg Tablet</title>
            <description>Vortioxetine 20 mg (one 20 mg tablet) orally, once on Day 1 in Period 1 in a fasted state plus Day 1 in Period 2 in a fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine Two 10 mg Tablets</title>
            <description>Vortioxetine 20 mg (two 10 mg tablets) orally, once on Day 1 in Period 1 in a fasted state plus Day 1 in Period 2 in a fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>MRTlast, ev: Mean Residence Time From Time 0 to the Time of the Last Quantifiable Concentration of Unchanged Lu AA21004</title>
          <population>Pharmacokinetic (PK) Analysis Set; PK analysis set included all treated participants who had no major protocol violations, completed the minimum element of the protocol, and had evaluable pharmacokinetic data.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.12" spread="1.8274"/>
                    <measurement group_id="O2" value="30.12" spread="1.8335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>λz: Apparent Elimination Rate Constant of Unchanged Lu AA21004</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose</time_frame>
        <population>Pharmacokinetic (PK) Analysis Set; PK analysis set included all treated participants who had no major protocol violations, completed the minimum element of the protocol, and had evaluable pharmacokinetic data.</population>
        <group_list>
          <group group_id="O1">
            <title>Vortioxetine One 20 mg Tablet</title>
            <description>Vortioxetine 20 mg (one 20 mg tablet) orally, once on Day 1 in Period 1 in a fasted state plus Day 1 in Period 2 in a fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine Two 10 mg Tablets</title>
            <description>Vortioxetine 20 mg (two 10 mg tablets) orally, once on Day 1 in Period 1 in a fasted state plus Day 1 in Period 2 in a fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>λz: Apparent Elimination Rate Constant of Unchanged Lu AA21004</title>
          <population>Pharmacokinetic (PK) Analysis Set; PK analysis set included all treated participants who had no major protocol violations, completed the minimum element of the protocol, and had evaluable pharmacokinetic data.</population>
          <units>1/Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01608" spread="0.0040090"/>
                    <measurement group_id="O2" value="0.01599" spread="0.0041766"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>T1/2z: Apparent Elimination Half-Life of Unchanged Lu AA21004</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose</time_frame>
        <population>Pharmacokinetic (PK) Analysis Set; PK analysis set included all treated participants who had no major protocol violations, completed the minimum element of the protocol, and had evaluable pharmacokinetic data.</population>
        <group_list>
          <group group_id="O1">
            <title>Vortioxetine One 20 mg Tablet</title>
            <description>Vortioxetine 20 mg (one 20 mg tablet) orally, once on Day 1 in Period 1 in a fasted state plus Day 1 in Period 2 in a fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine Two 10 mg Tablets</title>
            <description>Vortioxetine 20 mg (two 10 mg tablets) orally, once on Day 1 in Period 1 in a fasted state plus Day 1 in Period 2 in a fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>T1/2z: Apparent Elimination Half-Life of Unchanged Lu AA21004</title>
          <population>Pharmacokinetic (PK) Analysis Set; PK analysis set included all treated participants who had no major protocol violations, completed the minimum element of the protocol, and had evaluable pharmacokinetic data.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.36" spread="9.7694"/>
                    <measurement group_id="O2" value="46.44" spread="13.090"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE)</title>
        <time_frame>Up to Day 25</time_frame>
        <population>Safety Analysis Set; The safety analysis set included all participants who received at least one dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Vortioxetine One 20 mg Tablet</title>
            <description>Vortioxetine 20 mg (one 20 mg tablet) orally, once on Day 1 in Period 1 in a fasted state plus Day 1 in Period 2 in a fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine Two 10 mg Tablets</title>
            <description>Vortioxetine 20 mg (two 10 mg tablets) orally, once on Day 1 in Period 1 in a fasted state plus Day 1 in Period 2 in a fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE)</title>
          <population>Safety Analysis Set; The safety analysis set included all participants who received at least one dose of the study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With TEAE Related to Vital Sign</title>
        <time_frame>Up to Day 25</time_frame>
        <population>Safety Analysis Set; The safety analysis set included all participants who received at least one dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Vortioxetine One 20 mg Tablet</title>
            <description>Vortioxetine 20 mg (one 20 mg tablet) orally, once on Day 1 in Period 1 in a fasted state plus Day 1 in Period 2 in a fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine Two 10 mg Tablets</title>
            <description>Vortioxetine 20 mg (two 10 mg tablets) orally, once on Day 1 in Period 1 in a fasted state plus Day 1 in Period 2 in a fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAE Related to Vital Sign</title>
          <population>Safety Analysis Set; The safety analysis set included all participants who received at least one dose of the study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With TEAE Related to Clinical Laboratory Tests (Alanine Aminotransferase Increased)</title>
        <time_frame>Up to Day 25</time_frame>
        <population>Safety Analysis Set; The safety analysis set included all participants who received at least one dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Vortioxetine One 20 mg Tablet</title>
            <description>Vortioxetine 20 mg (one 20 mg tablet) orally, once on Day 1 in Period 1 in a fasted state plus Day 1 in Period 2 in a fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine Two 10 mg Tablets</title>
            <description>Vortioxetine 20 mg (two 10 mg tablets) orally, once on Day 1 in Period 1 in a fasted state plus Day 1 in Period 2 in a fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAE Related to Clinical Laboratory Tests (Alanine Aminotransferase Increased)</title>
          <population>Safety Analysis Set; The safety analysis set included all participants who received at least one dose of the study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With TEAE Related to 12-lead Electrocardiograms</title>
        <time_frame>Up to Day 25</time_frame>
        <population>Safety Analysis Set; The safety analysis set included all participants who received at least one dose of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Vortioxetine One 20 mg Tablet</title>
            <description>Vortioxetine 20 mg (one 20 mg tablet) orally, once on Day 1 in Period 1 in a fasted state plus Day 1 in Period 2 in a fasted state.</description>
          </group>
          <group group_id="O2">
            <title>Vortioxetine Two 10 mg Tablets</title>
            <description>Vortioxetine 20 mg (two 10 mg tablets) orally, once on Day 1 in Period 1 in a fasted state plus Day 1 in Period 2 in a fasted state.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAE Related to 12-lead Electrocardiograms</title>
          <population>Safety Analysis Set; The safety analysis set included all participants who received at least one dose of the study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Day 25</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Vortioxetine One 20 mg Tablet</title>
          <description>Vortioxetine 20 mg (one 20 mg tablet) orally, once on Day 1 in Period 1 in a fasted state plus Day 1 in Period 2 in a fasted state.</description>
        </group>
        <group group_id="E2">
          <title>Vortioxetine Two 10 mg Tablets</title>
          <description>Vortioxetine 20 mg (two 10 mg tablets) orally, once on Day 1 in Period 1 in a fasted state plus Day 1 in Period 2 in a fasted state.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

